{"status": "OK", "response": {"docs": [{"type_of_material": "Letter", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "To the Editor: You painted a picture of pharmaceutical companies as scheming materialists offering subtle bribes to doctors to get more drugs on the market (front page, May 16).", "headline": {"main": "When Drug Trials Hurt Patients; Scheming Materialists?"}, "abstract": "Letter from Dr Jack Geller says May 16 article painted picture of pharmaceutical companies as scheming materialists, but he had far different experience when he did collaborative research with Merck & Co on development of new drug", "print_page": "26", "word_count": 161, "_id": "4fd20c838eb7c8105d77be7a", "snippet": "To the Editor:    You painted a picture of pharmaceutical companies as scheming materialists offering subtle bribes to doctors to get more drugs on the market (front page, May 16).", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1999/05/20/opinion/l-when-drug-trials-hurt-patients-scheming-materialists-783145.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GELLER, JACK"}, {"name": "organizations", "value": "MERCK & CO"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": null, "document_type": "article", "pub_date": "1999-05-20T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "Biography", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "It is like visiting a boxer in his training camp a few days before the big fight. The display of muscle. The brassy predictions of victory. The forecast that the world will be changed after the dazed opponent has been carried from the ring feet first before a jeering crowd. But in this case the muscle consists of a HAL-sized computer, said to be the second most powerful in the world, and a ballroom-like chamber being equipped to receive $30 million worth of high-tech machines. The rivals are the Federal Government and the world's largest medical philanthropy. And yes, the world might really be changed just a little if the vaunted victory is achieved.", "headline": {"main": "The Genome's Combative Entrepreneur"}, "abstract": "Dr J Craig Venter is at work trying to decode human genome in a private endeavor at Celera, a division of PE Corp, that is competing with public consortium financed by National Institutes of Health and Wellcome Trust of London; public consortium breaks DNA in large fragments, maps the positions of the fragments on chromosomes and then sequences the fragments; Venter's approach is to fit the fragments together without a map; he regards the public consortium's strategy as inefficient, but some biologists believe he is pursuing a shotgun approach that could yield a nightmare of almost identical pieces; photo (L)", "print_page": "1", "word_count": 1920, "_id": "4fd1fbe28eb7c8105d75ab56", "snippet": "It is like visiting a boxer in his training camp a few days before the big fight. The display of muscle. The brassy predictions of victory. The forecast that the world will be changed after the dazed opponent has been carried from the ring feet first...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1999/05/18/science/the-genome-s-combative-entrepreneur.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "VENTER, J CRAIG"}, {"name": "organizations", "value": "PE CORP"}, {"name": "organizations", "value": "NATIONAL INSTITUTES OF HEALTH"}, {"name": "organizations", "value": "CELERA CORP"}, {"name": "organizations", "value": "WELLCOME TRUST"}, {"name": "subject", "value": "HUMAN GENOME PROJECT"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DEOXYRIBONUCLEIC ACID"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Nicholas", "lastname": "WADE"}], "original": "By NICHOLAS WADE"}, "document_type": "article", "pub_date": "1999-05-18T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "Series", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "If ever there was a wonder boy in the lucrative business of drug testing, it was Dr. Robert Fiddes. In just a few years, Dr. Fiddes transformed his sleepy medical practice here into a research juggernaut, recruiting patients for drug experiments at a breakneck pace. His success made him a magnet for an industry desperately scouring the nation for test subjects. Companies large and small showered him not only with more than 170 studies to conduct, but with millions of dollars in compensation for his work.", "headline": {"main": "A Doctor's Drug Trials Turn Into Fraud"}, "abstract": "Second article in two-part series, Research for Hire, on pharmaceutical renaissance in clinical testing of drugs on humans, in which patients have become commodities and which is fraught with conflicts of interest among doctors; focuses on weaknesses that have emerged in testing system in recent years, as pharmaceutical industry has switched from career researchers at academic medical centers, whose professional reputations are forged on quality of their data, to thousands of private-practice doctors to whom testing has become extremely lucrative sideline; while researchers now have enormous financial incentive to cheat, methods of monitoring their activities remain basically same; cites corruption at Southern California Research Institute run by Dr Robert Fiddes as example of ease with which testing system can be compromised; Fiddes who transformed sleepy medical practice in Whittier, Calif, into medical juggernaut is serving prison term for conducting research fraud--cutting corners, enrolling fictitious patients and fabricating data to keep millions of dollars flowing from drug industry; investigations were never initiated, even though Fiddes's employees alerted monitors to their suspicions; warnings were filed away, while Fiddes's sterling reputation as researcher grew; photos (L)", "print_page": "1", "word_count": 5442, "_id": "4fd1fbd98eb7c8105d75a6cf", "snippet": "If ever there was a wonder boy in the lucrative business of drug testing, it was Dr. Robert Fiddes.    In just a few years, Dr. Fiddes transformed his sleepy medical practice here into a research juggernaut, recruiting patients for drug experiments...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1999/05/17/business/a-doctor-s-drug-trials-turn-into-fraud.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "FIDDES, ROBERT"}, {"name": "organizations", "value": "SOUTHERN CALIFORNIA RESEARCH INSTITUTE"}, {"name": "subject", "value": "FRAUDS AND SWINDLING"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "SENTENCES (CRIMINAL)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "BIOGRAPHICAL INFORMATION"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Kurt", "lastname": "EICHENWALD"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By KURT EICHENWALD and GINA KOLATA"}, "document_type": "article", "pub_date": "1999-05-17T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "Series", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "When Thomas W. Parham visited his doctor in the summer of 1995, he expected just another routine checkup. But his doctor had something else in mind. The doctor, Peter Arcan, suggested Mr. Parham might want to join a study of a new drug to shrink enlarged prostates, according to records of the encounter. Mr. Parham was puzzled -- his prostate was fine. But Dr. Arcan brushed aside the retired metal worker's questions, saying the experimental drug might prevent future problems. Satisfied, Mr. Parham, a 64-year-old resident of La Habra, Calif., agreed to participate.", "headline": {"main": "Drug Trials Hide Conflicts for Doctors"}, "abstract": "Article Research for Hire, first of two, on clinical drug research that has become multimillion-dollar industry; hundreds of testing and drug companies working with private doctors have turned patients into 'commodities,' bought and traded as physicians are enticed into usingthem as test subjects; practice gives drug companies get access to vast new pool of subjects, but also raises serious ethical questions by injecting money into delicate doctor-patient relationship, usually without patient even realizing it; ten-month New York Times investigation studies contracts and other confidential documents that reveal system that fuels pharmaceutical renaissance, is fraught with conflicts of interest, places premium on speed and meeting quotas, and relies on Government and private monitoring that can be easily fooled; drug companies and contractors offer large payments to doctors, nurses and other medical staff to recruit patients, some getting finder's fees for merely referring patients to studies; companies use doctors as clinical investigators regardless of their speciality; example is Dr Peter Arcan's enlistment of patient Thomas W Parham in inappropriate prostate trial for SmithKline Beecham; other cases also cited; Drs David S Shimm, Jay Grossman, Robert M Califf and others on both sides of issue comment; photos; diagram tracing how typical drug comes to market (L)", "print_page": "1", "word_count": 7001, "_id": "4fd1fbe48eb7c8105d75ac6a", "snippet": "When Thomas W. Parham visited his doctor in the summer of 1995, he expected just another routine checkup. But his doctor had something else in mind.    The doctor, Peter Arcan, suggested Mr. Parham might want to join a study of a new drug to shrink...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/1999/05/16/business/drug-trials-hide-conflicts-for-doctors.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SHIMM, DAVID S"}, {"name": "persons", "value": "CALIFF, ROBRT M"}, {"name": "persons", "value": "PARHAM, THOMAS W"}, {"name": "persons", "value": "GROSSMAN, JAY"}, {"name": "persons", "value": "ARCAN, PETER"}, {"name": "organizations", "value": "SMITHKLINE BEECHAM"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Kurt", "lastname": "EICHENWALD"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By KURT EICHENWALD and GINA KOLATA"}, "document_type": "article", "pub_date": "1999-05-16T00:00:00Z", "section_name": "Health; Business"}], "meta": {"hits": 4, "offset": 0, "time": 34}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}